ArticleJCO oncology practice2026
Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma.
Article in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review.Annals of surgical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposePancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, even for patients diagnosed at a radiographically localized stage. Despite disease recurrence in most patients who undergo curative-intent therapy, national guidelines do not currently recommend comprehensive genomic profiling (CGP) until progression occurs following treatment. As the number of approved and investigational therapies expands for PDAC, ensuring access to early CGP data is critical for implementing molecularly informed treatment strategies.
methodsWe performed a single-institution, retrospective analysis of CGP utilization and treatment patterns in patients with localized PDAC who underwent curative-intent resection in the contemporary period during which CGP was recommended for all patients with advanced/recurrent disease (2019-2024).
resultsAmong 380 patients, 215 (56.5%) developed recurrence at a median follow-up time of 19.4 months. Of patients with documented recurrence, we found that 43.2% never underwent CGP, and among those who did have CGP performed, only 61.5% had access to these data before initiating postrecurrence systemic therapy. In terms of barriers to CGP, we found that earlier testing (within 2 months of surgery) improved access to CGP before initiation of postrecurrence treatment, whereas deferred testing was associated with a greater chance of molecularly uninformed treatment. We also found that patients whose surgery and systemic therapy were fragmented across centers were less likely to receive CGP (65.6%
conclusionA uniform strategy for ensuring patients with resected PDAC receive CGP may improve access to clinical trials and molecularly tailored treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.